367 related articles for article (PubMed ID: 29609578)
21. Role of Denosumab in Endoscopic Endonasal Treatment for Juvenile Clival Giant Cell Tumor: A Case Report and Review of the Literature.
Inoue A; Ohnishi T; Kohno S; Nishikawa M; Nishida N; Ohue S
World Neurosurg; 2016 Jul; 91():674.e1-6. PubMed ID: 27113403
[TBL] [Abstract][Full Text] [Related]
22. Histologic Spectrum of Giant Cell Tumor (GCT) of Bone in Patients 18 Years of Age and Below: A Study of 63 Patients.
Al-Ibraheemi A; Inwards CY; Zreik RT; Wenger DE; Jenkins SM; Carter JM; Boland JM; Rose PS; Jin L; Oliveira AM; Fritchie KJ
Am J Surg Pathol; 2016 Dec; 40(12):1702-1712. PubMed ID: 27526293
[TBL] [Abstract][Full Text] [Related]
23. H3F3 mutation status of giant cell tumors of the bone, chondroblastomas and their mimics: a combined high resolution melting and pyrosequencing approach.
Kervarrec T; Collin C; Larousserie F; Bouvier C; Aubert S; Gomez-Brouchet A; Marie B; Miquelestorena-Standley E; Le Nail LR; Avril P; Christophe Pagès J; de Pinieux G
Mod Pathol; 2017 Mar; 30(3):393-406. PubMed ID: 28059095
[TBL] [Abstract][Full Text] [Related]
24. Highly recurrent H3F3A mutations with additional epigenetic regulator alterations in giant cell tumor of bone.
Ogura K; Hosoda F; Nakamura H; Hama N; Totoki Y; Yoshida A; Ohashi S; Rokutan H; Takai E; Yachida S; Kawai A; Tanaka S; Shibata T
Genes Chromosomes Cancer; 2017 Oct; 56(10):711-718. PubMed ID: 28545165
[TBL] [Abstract][Full Text] [Related]
25. The two faces of giant cell tumor of bone.
Scotto di Carlo F; Whyte MP; Gianfrancesco F
Cancer Lett; 2020 Oct; 489():1-8. PubMed ID: 32502498
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic tools in the differential diagnosis of giant cell-rich lesions of bone at biopsy.
Rehkämper J; Steinestel K; Jeiler B; Elges S; Hekeler E; Huss S; Sperveslage J; Hardes J; Streitbürger A; Gosheger G; Wardelmann E; Baumhoer D; Trautmann M; Hartmann W
Oncotarget; 2018 Jul; 9(53):30106-30114. PubMed ID: 30046391
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathologic and molecular features of denosumab-treated giant cell tumour of bone (GCTB): Analysis of 21 cases.
Yang L; Zhang H; Zhang X; Tang Y; Wu Z; Wang Y; Huang H; Fu X; Liu J; Hogendoorn PCW; Cheng H
Ann Diagn Pathol; 2022 Apr; 57():151882. PubMed ID: 34995868
[TBL] [Abstract][Full Text] [Related]
28. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series.
Girolami I; Mancini I; Simoni A; Baldi GG; Simi L; Campanacci D; Beltrami G; Scoccianti G; D'Arienzo A; Capanna R; Franchi A
J Clin Pathol; 2016 Mar; 69(3):240-7. PubMed ID: 26338802
[TBL] [Abstract][Full Text] [Related]
29. The highly prevalent H3F3A mutation in giant cell tumours of bone is not shared by sporadic central giant cell lesion of the jaws.
Gomes CC; Diniz MG; Amaral FR; Antonini Guimarães BV; Gomez RS
Oral Surg Oral Med Oral Pathol Oral Radiol; 2014 Nov; 118(5):583-5. PubMed ID: 25442495
[TBL] [Abstract][Full Text] [Related]
30. H3F3A mutation as a marker of malignant giant cell tumor of the bone: A case report and review of literature.
Ratnagiri R; Uppin S
J Cancer Res Ther; 2023; 19(3):832-834. PubMed ID: 37470622
[TBL] [Abstract][Full Text] [Related]
31. The distinct clinical features of giant cell tumor of bone in pagetic and non-pagetic patients are associated with genetic, biochemical and histological differences.
Divisato G; Scotto di Carlo F; Pazzaglia L; Rizzo R; Coviello DA; Benassi MS; Picci P; Esposito T; Gianfrancesco F
Oncotarget; 2017 Sep; 8(38):63121-63131. PubMed ID: 28968976
[TBL] [Abstract][Full Text] [Related]
32. Pathogenesis of Osteosclerotic Change Following Treatment with an Antibody Against RANKL for Giant Cell Tumour of the Bone.
Rosario M; Takeuchi A; Yamamoto N; Hayashi K; Miwa S; Higuchi T; Abe K; Taniguchi Y; Aiba H; Tanzawa Y; Murakami H; Tsuchiya H
Anticancer Res; 2017 Feb; 37(2):749-754. PubMed ID: 28179326
[TBL] [Abstract][Full Text] [Related]
33. [DNA sequencing of H3F3A mutations in H3.3 immunohistochemistry-negative giant cell tumors of bone].
Gong LH; Zhang W; Sun XQ; Zhang M; Ding Y
Zhonghua Bing Li Xue Za Zhi; 2021 Mar; 50(3):190-193. PubMed ID: 33677880
[No Abstract] [Full Text] [Related]
34. A single-center experience with giant cell tumors of sphenoid bone and clivus.
Yaprak Bayrak B; Özcan E; Vural Ç; Emengen A; Çabuk B; Ceylan S
Tumori; 2021 Dec; 107(6):NP94-NP100. PubMed ID: 34374310
[TBL] [Abstract][Full Text] [Related]
35. Treatment of Clival Giant Cell Tumor: A Case Report and Literature Review.
Yang JY; Kang H; Kim YH
Brain Tumor Res Treat; 2024 Apr; 12(2):132-140. PubMed ID: 38742263
[TBL] [Abstract][Full Text] [Related]
36. PTHrP increases RANKL expression by stromal cells from giant cell tumor of bone.
Cowan RW; Singh G; Ghert M
J Orthop Res; 2012 Jun; 30(6):877-84. PubMed ID: 22102368
[TBL] [Abstract][Full Text] [Related]
37. Denosumab-treated giant cell tumor of bone. Its histologic spectrum and potential diagnostic pitfalls.
Roitman PD; Jauk F; Farfalli GL; Albergo JI; Aponte-Tinao LA
Hum Pathol; 2017 May; 63():89-97. PubMed ID: 28235628
[TBL] [Abstract][Full Text] [Related]
38. Histomorphometric Analysis of Pre- and Post-Denosumab-Treated Giant Cell Tumor of Bone.
Ud Din N; Umer M; Park YK
Int J Surg Pathol; 2020 Dec; 28(8):859-867. PubMed ID: 32429739
[No Abstract] [Full Text] [Related]
39. Denosumab-treated Giant Cell Tumor of Bone Exhibits Morphologic Overlap With Malignant Giant Cell Tumor of Bone.
Wojcik J; Rosenberg AE; Bredella MA; Choy E; Hornicek FJ; Nielsen GP; Deshpande V
Am J Surg Pathol; 2016 Jan; 40(1):72-80. PubMed ID: 26414220
[TBL] [Abstract][Full Text] [Related]
40. Anti-Histone H3.3 G34W antibody is a sensitive and highly specific immunohistochemistry marker for the diagnosis of Giant cell tumor of bone. A validation based on analysis of 198 cases from a single centre in India.
Kamble A; Hui M; Rao KN; Narayanan R; Reddy BR; Uppin SG; Chandrasekhar P
Indian J Pathol Microbiol; 2022; 65(3):617-629. PubMed ID: 35900490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
